

1 **TITLE:** CoViD-19 rRT-PCR Testing Capacity in Ghana; Indications of Preparedness for Marburg
2 virus Outbreak?

3
4 Eric NY Nyarko^{1*}, Justice Kumi², Emmanuel K Ofori¹, Richmond O. Ateko¹, Michael Appiah³, Afua
5 B. Adjei¹, Derrick N.D. Doodoo⁴, Broderick Yeboah Amoah⁵, Sandra ANA Crabbe¹, Ebenezer K
6 Amakye⁶, Seth D Amanquah¹, Christian Obirikorang^{7,8}, Henry Asare-Anane¹

7 ¹Department of Chemical Pathology, University of Ghana Medical School, University of Ghana

8 ²Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana.

9 ³Department of Medical Laboratory Technology, Accra Technical University

10 ⁴Department of Medical Laboratory Science, Baldwin University College

11 ⁵Department of Medical Laboratory Science, School of Biomedical and Allied Health Sciences, College
12 of Health Sciences, University of Ghana.

13 ⁶ Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, University for
14 Development Studies

15 ⁷Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University
16 of Science and Technology, Ghana

17 ⁸Global Health and Infectious Diseases Group, Kumasi Centre for Collaborative Research, Ghana

18

19

20 ***Corresponding author**

21 Eric NY Nyarko

22 Department of Chemical Pathology,

23 University of Ghana Medical School,

24 University of Ghana, Ghana

25 eynyarko@ug.edu.gh

26

27 **Abstract**

28 **Introduction:** Ghana, as of July 2022, has had 168,350 Real-Time Reverse Transcription-Polymerase
29 Chain Reaction (rRT-PCR)-confirmed cases of CoViD-19 infections and 1,458 deaths. Besides, 2
30 cases of Marburg virus diseases (MVD) were confirmed in the country within the same month. Both

31 CoViD-19 and MVD require rRT-PCR for diagnosis, however, rRT-PCR facilities are scarce in Ghana
32 – especially, hitherto, the CoViD-19 pandemic. The objectives of this study were to assess the current
33 testing capacity of CoViD-19 rRT-PCR in Ghana, and to make some recommendations in case of an
34 MVD outbreak, or recurrence of the CoViD-19 pandemic.

35 **Methods:** The study was cross-sectional. Questionnaires were administered to 100 health
36 professionals actively involved in the testing cycle of CoViD-19 across rRT-PCR testing institutions.
37 Responses with regards to CoViD-19 rRT-PCR testing, biosafety, and relationship with Surveillance
38 Outbreak Response Management and Analysis System (SORMAS), PanaBios and Zipline, were
39 obtained for 2020-through-2022. The responses were analyzed with Microsoft Excel office-365 and
40 SPSS v.23.

41 **Results:** Thirty-five (35) of the 53 testing institutions were in the Greater Accra Region, but none in
42 seven (7) regions of the country. Many (49%) were privately owned. Nine (9) different professionals
43 were involved in rRT-PCR testing. The testing institutions increased from 2 (in March 2020) to 53 by
44 June-ending 2022, and most (90%) had Biosafety Cabinet class II (BSCII). PPEs were inadequate
45 between march and June, 2020 (25%), but enough (100%) by June 2022. Zipline, SORMAS, and
46 PanaBios, respectively, saw transactions from 28%, 81%, and 77% of the institutions.

47 **Conclusion:** Ghana is adequately resourced for recurrence of CoViD-19, or any MVD outbreak, in
48 terms of diagnosis with rRT-PCR. However, the country needs redistribution of these testing
49 resources, expand the services of Zipline and SORMAS, satisfy additional biosafety requirements for
50 MVD testing and equip over 180 GeneXpert facilities to help in accessible and affordable testing.

51 **KEYWORDS:** CoViD-19, rRT-PCR, Testing, BSC, SORMAS, Zipline, Marburg virus

52

53 **KEY POINTS**

54 **What is already known on this topic:**

55 It is known that there are CoViD-19 PCR testing laboratories (outside the public health system) and
56 a drone service company available now in Ghana for transport of medical supplies, and samples
57 especially in the heat of the CoViD-19 pandemic – called Zipline.

58 **What this study adds:**

59 The findings of this study detail the number of these testing laboratories and the drone company -
60 including their presence or sites across the 16 regions of Ghana. It also illuminates on the biosafety
61 cabinet classes and other PPE status of the country, professionals involved in direct rRT-PCR testing,
62 the benefits of SORMAS and Zipline in managing the pandemic, cost of consumables and tests within
63 the 2 years of the pandemic, and what should be done(now) to make Ghana prepared for other
64 infectious viral outbreaks, like the Marburg virus.

65 **How this study might affect research, practice or policy:**

66 The study, based on its findings, recommend the redistribution of the rRT-PCR testing infrastructure
67 across the country, expand the services of Zipline and SORMAS, employ the use of existing Cepheid
68 GeneXperts in its rRT-PCR testing, and upgrade its biosafety cabinet class requirements to the level
69 able to contain other possible outbreaks like the hemorrhagic the Marburg virus, in terms of testing.

70 **Introduction**

71 The CoViD-19 pandemic has infected more than 574 million of the world's human population, with
72 a death rate of 6.3 million (1.1 %) as of 31st July, 2022.(1) In Ghana, there has been 168,350 Real-
73 Time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR) confirmed cases with 1,458
74 deaths (0.86%).(2) At the peak of the pandemic, especially within the 2nd and 3rd quarters of 2020,
75 the importance of rRT-PCR testing to clinical management, contact tracing, isolation of infected
76 persons and quarantine of same, were extremely important. Countries such as Germany and North
77 Korea, were able to manage the CoViD-19 pandemic effectively, because they were able to identify
78 and organize their testing capacity earlier.(3) In Ghana, there was a scarcity of nucleic acid
79 amplification tests (NAAT) infrastructure, particularly rRT-PCR equipment, and biosafety cabinets
80 (BSC) class II, capable of containing class 2 and 3 dangerous viruses, making testing within appropriate
81 turn-around times (TAT) nearly impossible

82 Currently, Ghana is within the peak and post- pandemic phases, and the demand for PCR testing may
83 continuously decline, despite the possible widespread availability of CoViD-19 PCR testing (i.e.
84 September 2022). Moreover, on the 1st of July, 2022, two (2) cases of Marburg virus (MV) infections
85 resulting in Marburg virus diseases (MVD), were confirmed in the Ashanti region in Ghana.(4)
86 Marburg virus diseases is a highly infectious disease that causes haemorrhagic fever.(5) The gold
87 standard for diagnosis require rRT-PCR as the SARS-CoV-2 virus which causes the CoViD-19
88 infectious disease. However, blood sample is required and occasionally buccal, nasopharyngeal or

89 oropharyngeal samples - required for CoViD-19.(5) Though they have similar early stage clinical
90 presentations,(6), MVD is haemorrhagic, has a high case fatality rate(CFR) averaging 50% (compared
91 with <5.0% for CoViD-19) . Marburg virus diseases has no specific antiviral agent, unlike CoViD-19,
92 it has no vaccine, and requires Biosafety cabinet class III (BSCIII) during testing.(5–7) This study was
93 done to assess the CoViD-19 pandemic’s testing response infrastructure - including rRT-PCR, Sample
94 transport, Health and Laboratory Information/Management Systems (HLIMS); and Biosafety
95 equipment - build-up (or capacity) so far in Ghana, in case of post-peak CoViD-19 recurrent or MVD
96 outbreak. The most popular HLIMS employed in this pandemic was the SORMAS and transportation
97 of samples outside major suburbs, towns and villages were mostly done by a drone service company
98 called Zipline. Zipline played a significant role in the management of the pandemic – especially when
99 the pandemic was at its peak. These include transport of samples between sample collection and
100 testing sites, and delivery of pharmaceutical and other medical supplies from its 6 main stations. These
101 stations were the Omenako, Mpanya and Anum in the Eastern Region, Vobsi in the North East region,
102 Sefwi Wiawso in Western North and Kete Krachi in the Oti region.

103 **Method**


104 The study design was a cross-sectional survey conducted across the 16 regions of Ghana between May
105 and July 2022. Questionnaire was initially prepared and reviewed by 10 different professionals who
106 were actively involved in the entire testing cycle, during the pandemic. The final structured
107 questionnaire was administered to 100 health professionals who are actively involved in different
108 aspects of the CoViD-19 pandemic (especially in testing) across 53 CoViD-19 rRT-PCR registered
109 institutions, consisting of 58 centres (ie 3 of the institutions had 2 or 3 testing centers) in Ghana.
110 Seventy-two (72) of the health professionals who were able to respond to at least 21 (75%) of the 28
111 questions relevant to the objectives of the study were included in the data analysis. The response rate
112 (or ‘better’ adequate response rate) was 72%. The respondents included Medical Laboratory Scientists
113 (MLS), Research Scientists, Laboratory Technologists and Technicians, Microbiologists, Fulfilment
114 Operations Professionals (FOP), Laboratory Physicians, Lecturers, Molecular Biologists and
115 Veterinary Officers. Others included a Data Entry Clerk, and a PCR Technician. Responses to
116 questions such as the location of the testing facility, rRT-PCR equipment in-use, date of
117 commencement of rRT-PCR testing, biosafety, costs of reagents and tests, turn-around-times (TAT)
118 of tests, the average number of tests per day, transactions with Surveillance Outbreak Response
119 Management and Analysis System (SORMAS), PanaBios and Zipline were obtained for 2020, 2021

120 and 2022. The responses were entered into Microsoft Excel office-365 and analyzed, together with
121 SPSS v.23.(8,9)

122

123 Results

124 Thirty-five (66%) of the 53 rRT-PCR testing institutions were found in the Greater Accra Region,
125 5(9%) in the Ashanti, 3 (5%) in western, 2(4%) in each of Eastern, Northern, Savannah and Upper
126 East; while Oti and Volta had 1(2%) each (**Figure 1a**). None was found in Ahafo, Brong Ahafo, Bono
127 East, Central, North-East, Upper West, and Western North regions of the country. Many, 26 (49%)
128 of the institutions are privately owned, 21 (40%) are publicly owned, 5 (9%) are public-private-
129 partnerships (PPP) and 1 (2%) is a non-governmental organization (an NGO) owned (**Figure 2**).



130

131 Nine (9) different professionals and experts were involved in rRT-PCR testing (i.e. bench work);
132 including Medical Laboratory Scientists (MLS), 30 (59%), Research Scientists, 7 (13%), 3 (6%) each
133 of Laboratory Technicians and Microbiologists, 2 (4%) each of Laboratory Physicians, Molecular
134 Biologist and Veterinary officers, and 1(2%) each of PCR technician and Laboratory technician
135 (**Figure 3**). Other professionals who were involved (indirectly) in the testing cycle (and were included

136 in the study) were 2 fulfilment operation professionals (FOP) from Zipline and a data entry clerk from
 137 SORMAS.




Figure 2: Shows types of Ownership of rRT-PCR testing institutions. NGO: Non-Governmental Organization; PPP: Private public partnership




Figure 3: Shows the various expertise involved in rRT-PCR bench work

138
 139 The number of rRT-PCR testing institutions increased from 2 in march 2020 to 35 by October 2020,
 140 40 by February, 2021; 48 by June 2021; 51 by October 2021 and 53 by June 2022 (**Figure 4**).




Figure 4: Shows the number of rRT-PCR testing institutions from March 2020 to June 2022

141
 6

142 Many (32%) of the 20 rRT-PCR equipment brands were either Sansure MA-6000 RT PCR or Bio-
143 Rad CFX 96 DX RT PCR. Three (3) of the institutions commenced testing in mid-to-ending of March
144 2020. The number increased to 35 by October 2020, 40 by February, 2021; 48 by June 2021; 51 by
145 October 2021 and 53 by June 2022. There has been no new testing institution up to July 2022. Twenty-
146 seven, 48 (90%) of 53 testing institutions had Biosafety cabinet class II (BSCII), 3(6%) had BSC III,
147 and 2 (4%) had glove boxes – which are essentially BSC III (*Figure 5*).




Figure 5: Number of Biosafety Cabinet (BSC) classes available in the rRT-PCR testing laboratories

148
149 There were 25%, 96% and 100% of personal protective equipment (PPE) adequacy in 2020, 2021 and
150 2022 respectively. The average cost of reagents and other consumables per test, and the cost of tests
151 to patients have decreased from GHC 180(\$23) (in June 2020) to GHC 112(\$14) (June 30, 2022) and
152 GHC 348(\$45) (in June 2020) to GHC 314(\$40) (by June 30, 2022) respectively. Turn-around-time
153 (TAT) for patients' test reports decreased from an average of 26 hours in June 2020 to 16 hours in
154 2021 and 19 hours by June 30, 2022. The average number of tests done by each laboratory per day
155 within the same periods were 388, 558 and 289 respectively. The institutions that had some activity or
156 transactions with Zipline, SORMAS and PanaBios were 28%, 81% and 77% respectively. Eleven,
157 11(21%) of those with some transactions with Zipline received samples via them, 3 (5%) both received
158 and dispatched samples via Zipline, and 1(2%) only dispatched samples through Zipline. Thirty-eight,
159 38(72%) of the institutions (all in the Greater Accra and Ashanti Regions) had no dealings with
160 Zipline.

161

162 Discussions

163 This study aimed to determine CoViD-19 rRT-PCR testing capacity in Ghana from March 2020 to
164 July 2022, and to make some recommendations, which might help in dealing with other outbreaks
165 such as the haemorrhagic Marburg Virus Disease (MVD) – in terms of testing. Ghana is (currently)
166 adequately resourced for possible recurrence of CoViD-19 or Marburg virus (MV) outbreak in terms
167 of rRT-PCR testing, however, there will be a need for redistribution of the available resources and
168 increasing of the safety materials and equipment such as PPEs and BSCs class III across the 16 regions,
169 to achieve success in case of such outbreak. This must be done, considering population density of
170 each region vis-à-vis demand and supply forces. In March 2020, when Ghana recorded its first 2 cases,
171 rRT-PCR testing was the most important requirement for the identification of infected persons, to
172 contact tracing, isolating and quarantining, and to clinically design management strategies for infected
173 persons.(10) Evolution of the number of testing institutions was examined in this study. Before March
174 2020, the Noguchi Memorial Institute for Medical Research (NMIMR), the National Public Health
175 Reference Laboratory (NPHRL), and the Kumasi Centre for Collaborative Research (KCCR) were
176 ‘adequately resourced’ to test for CoViD-19 virus using the rRT-PCR. By June, 2020, there were 20
177 CoViD-19 PCR testing institutions, mostly concentrated within the Accra metropolis of the Greater
178 Accra Region. These had an equal private-to-public ownership ratio - with a few scattered in other
179 major cities such as Takoradi in the Western Region and Kumasi in the Ashanti Region.

180 The rate with which Ghana developed this testing capacity is remarkable (**Figure 4**), and it was
181 comparable to what had been reported in few African countries. (11) These 53 institutions exclude
182 the majority of Ghana Health Service (GHS) and other institutions with Cepheid GeneXpert
183 infrastructure – capable of CoViD-19 rRT-PCR testing. There are over 130 GeneXpert devices in
184 facilities across the country,(12) often used for *Mycobacterium tuberculosis* testing.(13) This study found
185 the availability of the rRT-PCR model equipment in only 9 of the 16 regions. There were none in the
186 Ahafo, Brong Ahafo, Bono East, Central, North-East, Upper West, and Western North regions of
187 the country. Centralizing the testing facilities to few locations negatively affects the management of
188 any pandemic, as has been experienced in countries like Ecuador.(14) Hence, the resourcing of the
189 GeneXperts CoViD-19 rRT-PCR specific cartridges and other biosafety requirements, will make
190 available more than 180 facilities able to do the rRT-PCR required for CoViD-19 or MVD diagnosis.
191 Such provisions will result in at least 3(2%) rRT-PCR facilities in the Ahafo region, 23(12%) in Ashanti,
192 7(4%) in Bono East, 5(3%) each in Brong Ahafo, Savannah and Western North; 10(5%) in Central,

193 21(11%) in Eastern, 46(25%) in Greater Accra, and 6(3%) each in Northern and Oti (*Figure 1b*).
194 Others will include, 8(4%) in Upper East, 4(2%) in Upper West, 12(6%) in Volta, and 8(4%) in
195 Western. Besides, there will be 17 (9%) of these testing devices available in Ghanaian research
196 institutions, teaching hospitals, public health reference laboratories and at deprived and ‘difficult-to-
197 reach’ locations. This will help build the capacity of local professionals through training, reduce testing
198 cost, and reduce the TAT. It will also increase accessibility and rapid response to CoViD-19 or other
199 viral outbreaks such as the Marburg virus -which has a higher Case fatality rate (CFR) (of 50%),
200 compared to CoViD-19.

201 At the genesis of the pandemic in 2020, PPEs were scarce – even for health professionals involved in
202 patient contact, sample collection and testing.(15) However, by June 2022, PPEs were adequate for
203 these purposes (i.e. 25% adequacy of PPEs in 2020 compared to 100% in 2022). In case of a Marburg
204 Virus (MV) outbreak, safe sample collection, transport and testing for these risk group 4 pathogens
205 would require all PPEs for CoViD-19 including (K)N95 Medical masks, eye protection (goggles),
206 gloves, disposable gowns, and face shields. In addition, there would be a need for (personal) positive
207 pressure suits or additional protection over laboratory clothing, such as solid-front gowns with tight-
208 fitting wrists, two pairs of latex (preferably rubber) gloves, and an approved particulate respirator (e.g.,
209 N95 or higher), and impermeable cleanable footwear with its-impermeable (disposable) covers.(16)
210 Also, there would be the need for containment level 4 facilities with a minimum of BSC class III for
211 most laboratory procedures, and from this study we have just a few of such BSCs, but are mostly
212 concentrated in the Greater Accra and Ashanti regions. Thus, more of BSC class III are required.
213 This study found a reduction in the average cost of reagents and consumables per test, and a decline
214 in the number and cost of tests from June 2020, through to June 2022. These reductions could be as
215 a result of increases in the number of the testing service outlets/institutions, opening of the country’s
216 border for imports (there by increasing the supply side of resources), vaccination against the virus,
217 reduced public restrictions, and the country being in the post-peak stage of the pandemic – all of
218 which affect the supply and demand forces for the rRT-PCR testing. Similar findings have been
219 reported in some African countries, including South Africa and Nigeria.(17,18)

220 All the participants from the public testing facilities couldn’t tell the cost of the PCR reagents and
221 consumables per test, but most from the commercial private and public-private-partnered (PPP)
222 institutions were able to provide such costs. The average cost of testing (reagents and other direct
223 consumables) declined by 38% from June 2020, and 20% from June 2021. These declines in average

224 cost of testing, and that of the test prices could be due to equipment placement, and
225 reagent/consumable high-purchase services expanded by the players (in the industry) within the mid-
226 2021. Other factors such as the increasing in the number of suppliers, may have contributed to these
227 trends in prices. The average cost of tests within the same period decreased from GHC 349 (\$45) in
228 2020/21 to GHC 314 (\$40) by June 2022. It could be said from these, that an average of GHC 168
229 (\$22) (i.e.93%), GHC198 (\$25) (130%), and GHC202(\$26) (180%) direct-gross profits were made per
230 test each year (ending) June 2020, June 2021 and June 2022 respectively. These findings have been
231 collaborated by other reports from other African countries.(17,18) The average number of CoViD-19
232 PCR tests done by each laboratory increased from 388/day (in 2020) to 558/day (in 2021) and has
233 declined to 289/day by June 2022. These decreases in costs and number of tests (especially from the
234 2nd quarter of 2022) could be due to availability and increased access to vaccines, reduced infection
235 prevalence and incidence of the virus, acquisition of immunity and likely reduced virulence of the virus
236 (at the post-peak phase). The reduction in, and non-patronage of the Zipline services in the Greater
237 Accra region could be due to the proximity of patients to many testing institutions within the region.
238 It is also significant to note that, the North East region, which lacks a CoViD-19 rRT-PCR testing
239 institution could dispatch its samples to a nearby region with these drones, since there is a drone
240 service centre at Vobsi in the West Mamprusi Municipality of the region.

241 In a pandemic like CoViD-19, testing must be linked to public and community health information
242 management systems to help in decisions on surveillance, patient management, contact tracing, and
243 further testing. By June 30th 2022, most, 43 (81%) of the testing institutions were in-putting their
244 CoViD-19 laboratory data on the SORMAS platform to help monitor and survey some
245 epidemiological characteristics of the CoViD-19 pandemic. This activity also helped in the
246 management of the pandemic, as decisions were mostly based on reliable data within Ghana and by
247 extension, West Africa. Besides, most, 41, (77%) of the institutions had PanaBios certification and
248 validation, which gave some international permissions to travelers and states with regards to their
249 CoViD-19 infectious status, through the PanaBios Trusted Travel platform.

250 This study strongly recommends that, all testing institutions dealing with pathogens of public health
251 importance, concern, epidemic or pandemics, henceforth, must compulsorily be on surveillance
252 platforms such as the SORMAS to help in informed surveillance and monitoring. Also, the number
253 of locations and services of Zipline, especially in the seven regions which are currently without actual
254 rRT PCR testing facilities need to be expanded. When this is done widely, the country could limit the

255 number of testing institutions across the remote parts of the country – thus saving costs and reducing
256 the risk of infections that might occur due to personal(human) delivery services and community
257 fallouts. In addition to these, this transport technology may be employed for other health services –
258 such as the transport of blood products for transfusion within the Ghana health system and in any
259 infectious outbreak. Moreover, with these findings and the knowledge of CoViD-19 rRT-PCR testing
260 techniques, resourcing the GeneXpert devices and facilities with CoViD-19 rRT-PCR reagents (or
261 MV reagents -in MV outbreak), consumables, PPEs and other biosafety devices are recommended.

262

263 **Conclusions**

264 Through the CoViD-19 pandemic, Ghana has built adequate capacity for molecular testing and is
265 adequately resourced for recurrence of CoViD-19 or Marburg virus outbreak in terms of diagnosis
266 with rRT-PCR. However, Ghana needs redistribution of these resources, satisfy additional safety
267 requirements for Marburg virus testing and equip over 180 GeneXpert facilities with the additional
268 infrastructure and materials required for testing. There is also a need to expand the services of infection
269 control centers in case of hemorrhagic epidemic or pandemic. It is recommended that, all testing
270 institutions dealing with pathogens of public health concern, henceforth, must compulsorily be on
271 surveillance platforms such as the SORMAS to help in informed surveillance and monitoring. The
272 CoViD-19 pandemic has brought many health, social and economic challenges. However, Ghana now
273 has adequate testing capacity for diagnosis. There are now adequate PPEs, improved data
274 management, technologies for transport of health resources, and an added opportunity to improve, in
275 case of an outbreak by other viruses like the Marburg virus.

276 **Abbreviations**

277 rRT-PCR: Real-Time Reverse Transcription-Polymerase Chain Reaction

278 CoViD-19: SARS – COV-2 Disease 2019

279 MV: Marburg Virus

280 MVD: Marburg Virus Disease

281 NAAT: Nucleic acid amplification testing

282 PPS: Positive Pressure Suit

283 GHS: Ghana Health Service

284 WHO: World Health Organization

285 SORMAS: Surveillance Outbreak Response Management and Analysis System

286 TAT: Average turn-around-time per test per patient

287 CDC: Centre for Disease Control and Prevention, USA

288 BSC: Biosafety Cabinet

289 PPE: Personal Protective Equipment

290

291

292 **DECLARATIONS**

293 **Acknowledgement**

294 The authors acknowledge the efforts of the entire staff of the department of Chemical Pathology of
295 the University of Ghana Medical School, and all the professionals who took time off their busy
296 schedules to respond to our questionnaire, especially the reviewers of the questionnaire. The authors
297 are also grateful to all the participating institutions, especially those who responded to phone calls on
298 follow-ups and those who allowed them into their facilities to verify and confirm some responses.

299 **Authors' contributions**

300 ENYN was involved in conceptualization, methodology, software, supervision, validation, Writing –
301 original draft, Writing – review & editing; JK, EKO, DD, EKA, CO & HAA were involved in
302 methodology, supervision, software, data analysis, writing – original draft, writing – review & editing;
303 ROA, MA, ABA, BYA, SAC & SDA contributed in validation, writing – review & editing. All authors
304 read and approved the manuscript before submission

305 **Funding**

306 This research did not receive any specific grant from funding agencies in the public, commercial, or
307 not-for-profit sectors.

308 **Availability of data and materials**

309 The datasets used and/or analyzed during the current study are available from the corresponding
310 author on reasonable request.

311 **Ethical Considerations and consent to participate**

312 Not Applicable

313 **Competing interests**

314 The authors declare that they have no competing interests.

315 **Consent for publication**

316 Not applicable.

317

318 **REFERENCES**

- 319 1. World Health Organization W. COVID-19 Weekly Epidemiological Update. World Heal
320 Organ. 2022;Edition 10(August).
- 321 2. GHS GHS. Covid-19 Update. Covid-19 Update. 2022.
- 322 3. Acheampong Godfred, Michael Owusu, Bernard Nkrumah, Priscilla ObengBoadi, David A.
323 Opare, David J. Sambian PA& CW. Laboratory capacity in COVID-19 diagnosis and the
324 need to enhance molecular testing in Ghana Laboratory capacity in COVID-19 diagnosis and
325 the need to enhance molecular. Glob Secur Heal Sci Policy [Internet]. 2021;6(1):10–7.
326 Available from: <https://doi.org/10.1080/23779497.2021.1908157>
- 327 4. World Health Organization W. Ghana reports first-ever suspected cases of Marburg virus
328 disease. 2022.
- 329 5. CDC, Diseases NC for E and ZI, Division of High-Consequence Pathogens and Pathology
330 (DHCPP) C. Marburg Hemorrhagic Fever. CDC Factsheet. 2022.
- 331 6. Osaretin C, Emeka F, Mohanan P, Salma M, Saleem A, Ahmed U, et al. Marburg virus
332 disease outbreak amidst COVID-19 in the Republic of Guinea: A point of contention for the
333 fragile health system? Clin Epidemiol Glob Heal. 2020;13 (2022)(January):2020–3.
- 334 7. CDC. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition | CDC

- 335 Laboratory Portal | CDC. US Dep Heal Hum Serv [Internet]. 2020; Available from:
336 <https://www.cdc.gov/labs/BMBL.html>?CDC_
337 AA_refVal=[https%3A%2F%2Fwww.cdc.gov%2Fbiosafety%2Fpublications%2Fbmb15%2Fi](https://www.cdc.gov/biosafety/publications/bmb15/index.htm)
338 [ndex.htm](https://www.cdc.gov/biosafety/publications/bmb15/index.htm)
- 339 8. Corporation M. Microsoft Office-365 Excel [Internet]. 2018. Available from:
340 <https://office.microsoft.com/excel>.
- 341 9. IBM Corp. IBM Corp SPSS version 23 [Internet]. 2022. Available from:
342 [https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-](https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-a9ae-3856d5d4ea8b%40sessionmgr101)
343 [a9ae-3856d5d4ea8b%40sessionmgr101](https://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=31c18559-0cab-41ef-a9ae-3856d5d4ea8b%40sessionmgr101)
- 344 10. World Health Organizaton. Prevention, identification and management of health worker
345 infection in the context of COVID-1. *WwwWhoInt* [Internet]. 2020;58(12):1–4. Available
346 from: <https://apo.who.int/publications/i/item/10665-336265>
- 347 11. Amukele T, Spence RN. African countries established COVID-19 testing in one month:
348 Here’s how they did it. *Afr J Lab Med*. 2021;10(1):1–6.
- 349 12. Dennis A-G. Is Ghana against the use of GeneXpert and resourcing clinical laboratories for
350 COVID-19 testing? [Internet]. 2020. Available from:
351 <https://adugyasidennis.com/index.php/2020/07/21/>
- 352 13. Aninagyei E, Ayivor-Djanie R, Attoh J, Dakorah MP, Ginko MN, Acheampong DO.
353 Molecular detection of Mycobacterium tuberculosis in blood stained sputum samples using
354 GeneXpert PCR assay. *Diagn Microbiol Infect Dis* [Internet]. 2021;100(3):115363. Available
355 from: <https://doi.org/10.1016/j.diagmicrobio.2021.115363>
- 356 14. Torres I, Sippy R, Sacoto F. Assessing critical gaps in COVID-19 testing capacity: the case of
357 delayed results in Ecuador. *BMC Public Health*. 2021;21(1):1–8.
- 358 15. Afulani PA, Gyamerah AO, Nutor JJ, Laar A, Aborigo RA, Malechi H, et al. Inadequate
359 preparedness for response to COVID-19 is associated with stress and burnout among
360 healthcare workers in Ghana. *PLoS One* [Internet]. 2021;16(4 April):1–20. Available from:
361 <http://dx.doi.org/10.1371/journal.pone.0250294>
- 362 16. World Health Organization W. Marburg virus disease. Vol. 14, Operational Support &

- 363 Logistics Disease Commodity Packages. 2018.
- 364 17. Donna Marrie P. private-labs-in-south-africa-voluntarily-agree-to-lower-prices-for-covid-19-
365 pcr-tests-following-investigation-by-countrys-competition-commission. Dark Daily.
366 2022;2003–5.
- 367 18. Kanabe M. Covid-19-lagos-announces-reduction-in-pcr-test-fees. Premium Times Nigeria.
368 2022;508060.
- 369




Figure 5: Number of Biosafety Cabinet (BSC) classes available in the rRT-PCR testing laboratories